917 related articles for article (PubMed ID: 28436755)
41. Mucosal immunisation: adjuvants and delivery systems.
Moyle PM; McGeary RP; Blanchfield JT; Toth I
Curr Drug Deliv; 2004 Oct; 1(4):385-96. PubMed ID: 16305400
[TBL] [Abstract][Full Text] [Related]
42. Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges.
Holmgren J; Czerkinsky C; Eriksson K; Mharandi A
Vaccine; 2003 Jun; 21 Suppl 2():S89-95. PubMed ID: 12763689
[TBL] [Abstract][Full Text] [Related]
43. Norovirus (NoV) specific protective immune responses induced by recombinant P dimer vaccine are enhanced by the mucosal adjuvant FlaB.
Verma V; Tan W; Puth S; Cho KO; Lee SE; Rhee JH
J Transl Med; 2016 May; 14(1):135. PubMed ID: 27184355
[TBL] [Abstract][Full Text] [Related]
44. Beyond adjuvants: Antagonizing inflammation to enhance vaccine immunity.
Alter G; Sekaly RP
Vaccine; 2015 Jun; 33 Suppl 2():B55-9. PubMed ID: 26022570
[TBL] [Abstract][Full Text] [Related]
45. Recent developments in vaccine delivery systems.
O'Hagan DT
Curr Drug Targets Infect Disord; 2001 Nov; 1(3):273-86. PubMed ID: 12455401
[TBL] [Abstract][Full Text] [Related]
46. Selection of adjuvants for vaccines targeting specific pathogens.
Sarkar I; Garg R; van Drunen Littel-van den Hurk S
Expert Rev Vaccines; 2019 May; 18(5):505-521. PubMed ID: 31009255
[TBL] [Abstract][Full Text] [Related]
47. [Vaccine adjuvant].
Aoshi T; Ishii KJ
Nihon Rinsho; 2011 Sep; 69(9):1547-53. PubMed ID: 21922751
[TBL] [Abstract][Full Text] [Related]
48. Chitosan-based Nanoparticles in Mucosal Vaccine Delivery.
Mehrabi M; Montazeri H; Mohamadpour Dounighi N; Rashti A; Vakili-Ghartavol R
Arch Razi Inst; 2018 Sep; 73(3):165-176. PubMed ID: 30280836
[TBL] [Abstract][Full Text] [Related]
49. Generation of improved mucosal vaccines by induction of innate immunity.
Lavelle EC
Cell Mol Life Sci; 2005 Dec; 62(23):2750-70. PubMed ID: 16237500
[TBL] [Abstract][Full Text] [Related]
50. A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants.
Fujihashi K; Koga T; van Ginkel FW; Hagiwara Y; McGhee JR
Vaccine; 2002 Jun; 20(19-20):2431-8. PubMed ID: 12057597
[TBL] [Abstract][Full Text] [Related]
51. ISCOMATRIX™ adjuvant reduces mucosal tolerance for effective pulmonary vaccination against influenza.
Timothy AA; Tokanovic A; Snibson KJ; Edwards SJ; Pearse MJ; Scheerlinck JP; Sutton P
Hum Vaccin Immunother; 2015; 11(2):377-85. PubMed ID: 25692970
[TBL] [Abstract][Full Text] [Related]
52. Biomaterials as vaccine adjuvants.
Jones KS
Biotechnol Prog; 2008; 24(4):807-14. PubMed ID: 19194892
[TBL] [Abstract][Full Text] [Related]
53. Nasal and pulmonary vaccine delivery using particulate carriers.
Jia Y; Krishnan L; Omri A
Expert Opin Drug Deliv; 2015 Jun; 12(6):993-1008. PubMed ID: 25952104
[TBL] [Abstract][Full Text] [Related]
54. All things mucosal.
Thanavala Y; Lavelle E; Ogra P
Expert Rev Vaccines; 2009 Feb; 8(2):139-42. PubMed ID: 19196192
[TBL] [Abstract][Full Text] [Related]
55. Can mucosal adjuvants contribute to the induction of immunological memory induced via unconjugated T-cell-independent antigens?
Romeu B; Gonzalez E; Lastre M; Pérez O
J Drug Target; 2012 Jul; 20(6):502-8. PubMed ID: 22632258
[TBL] [Abstract][Full Text] [Related]
56. CAF01 liposomes as a mucosal vaccine adjuvant: In vitro and in vivo investigations.
Christensen D; Foged C; Rosenkrands I; Lundberg CV; Andersen P; Agger EM; Nielsen HM
Int J Pharm; 2010 May; 390(1):19-24. PubMed ID: 19879346
[TBL] [Abstract][Full Text] [Related]
57. Mechanisms of vaccine adjuvanticity at mucosal surfaces.
Foss DL; Murtaugh MP
Anim Health Res Rev; 2000 Jun; 1(1):3-24. PubMed ID: 11706842
[TBL] [Abstract][Full Text] [Related]
58. Innate immunity and vaccine.
Seya T
Vaccine; 2010 Nov; 28(50):8041-2. PubMed ID: 20849873
[TBL] [Abstract][Full Text] [Related]
59. Adjuvants for swine vaccines: Mechanisms of actions and adjuvant effects.
Charerntantanakul W
Vaccine; 2020 Oct; 38(43):6659-6681. PubMed ID: 32888738
[TBL] [Abstract][Full Text] [Related]
60. The use of a mutant TNF-alpha as a vaccine adjuvant for the induction of mucosal immune responses.
Kayamuro H; Abe Y; Yoshioka Y; Katayama K; Nomura T; Yoshida T; Yamashita K; Yoshikawa T; Kawai Y; Mayumi T; Hiroi T; Itoh N; Nagano K; Kamada H; Tsunoda S; Tsutsumi Y
Biomaterials; 2009 Oct; 30(29):5869-76. PubMed ID: 19646748
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
